Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “buy” rating reiterated by equities researchers at SunTrust Banks, Inc. in a report released on Friday. They currently have a $61.00 price target on the specialty pharmaceutical company’s stock. SunTrust Banks, Inc.’s price objective points to a potential upside of 45.07% from the stock’s current price.

A number of other equities analysts have also weighed in on SUPN. Piper Jaffray Companies set a $41.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, October 29th. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Cantor Fitzgerald restated a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Cowen and Company restated a “buy” rating and set a $50.00 target price on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $49.78.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at $42.05 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.74 and a current ratio of 1.94. The firm has a market cap of $2,104.01, a P/E ratio of 36.40, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. research analysts predict that Supernus Pharmaceuticals will post 1.04 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “SunTrust Banks, Inc. Reaffirms “Buy” Rating for Supernus Pharmaceuticals, Inc. (SUPN)” was published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/04/suntrust-banks-inc-reaffirms-buy-rating-for-supernus-pharmaceuticals-inc-supn.html.

In other news, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the completion of the transaction, the vice president now owns 17,500 shares of the company’s stock, valued at approximately $791,525. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold a total of 153,709 shares of company stock valued at $7,223,108 in the last three months. 6.70% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kornitzer Capital Management Inc. KS increased its position in Supernus Pharmaceuticals by 49.5% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 1,245,170 shares of the specialty pharmaceutical company’s stock worth $16,735,000 after purchasing an additional 412,280 shares in the last quarter. Neumeier Poma Investment Counsel LLC boosted its holdings in Supernus Pharmaceuticals by 1.6% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after acquiring an additional 14,430 shares during the period. GSA Capital Partners LLP boosted its holdings in Supernus Pharmaceuticals by 2.4% in the 4th quarter. GSA Capital Partners LLP now owns 219,572 shares of the specialty pharmaceutical company’s stock worth $2,951,000 after acquiring an additional 5,193 shares during the period. BlackRock Fund Advisors boosted its holdings in Supernus Pharmaceuticals by 1.1% in the 1st quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock worth $43,112,000 after acquiring an additional 31,238 shares during the period. Finally, Juncture Wealth Strategies LLC boosted its holdings in Supernus Pharmaceuticals by 0.8% in the 1st quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after acquiring an additional 433 shares during the period. 95.06% of the stock is owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.